ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases. Using our proprietary discovery platform for targeted (epitope-specific) immunotherapy, ImmusanT is developing a therapy and personalized diagnostics for celiac disease and is expanding to other autoimmune diseases including Type 1 diabetes.
We are now recruiting for clinical trials in celiac disease.
February 6, 2018
ImmusanT to Present at the 2018 BIO CEO & Investor Conference
One Kendall Square
Cambridge, MA 02139